Zuen Ren, M.D., Ph.D.
@ZuenRen
Graduate from @EinsteinMed Physician-scientist looking for cure for breast cancer working in @MGHCancerCenter @harvardmed
ID:880189137852215296
28-06-2017 22:20:18
195 Tweets
169 Followers
234 Following
Ludwig Harvard Medical School's Wu, Bogang presented at #AACR24 his research into the systematic identification of biochemical pathways associated with breast cancer cells' sensitivity to antibody-drug conjugates, a still-young but rapidly growing class of cancer therapies.
Ludwig Harvard Medical School's Zuen Ren, M.D., Ph.D. presented his research at #AACR24 in a poster titled, 'Multiomics analysis unravels tumor metabolic reprogramming and potential resistance mechanism(s) to curative therapy in triple negative breast cancer.'
#AACR24 honored to receive this recognition from the AACR! Many thanks to the AACR! AACR & the support from my home institute @ #EllisenLab MGH Breast Oncology Mass General Cancer Center
This will be a long-lasting game changer at and far beyond Einstein. Thank you, Dr. Gottesman!
Albert Einstein College of Medicine - Official EinsteinSCI
$1 Billion Donation Will Provide Free Tuition at a Bronx Medical School nytimes.com/2024/02/26/nyrβ¦
Many thanks for publishing our work β¦Nature Portfolioβ© British Journal of Cancerβ© β¦Springer Natureβ© Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1Ξ± | British Journal of Cancer nature.com/articles/s4141β¦
Thank you to Dr. Leif Ellisen MGH Breast Oncology for kicking off our Mass General Cancer Center Multidisciplinary Breast Cancer Rounds this academic year and speaking on preoperative therapy and chemoresistant triple-negative #breastcancer !
Thanks so much to the AACR! Many more exciting research π§ to come! AACR Mass General Cancer Center MGH Breast Oncology
Huge thanks for the award AACR Foundation @AACR Pfizer Inc. It is such a recognition to me. With the support from our team MGH Breast Oncology Mass General Cancer Center, I aimed to find cure for BRCA1/2 mutation-related breast cancer